2022
DOI: 10.1016/j.csbj.2022.10.017
|View full text |Cite
|
Sign up to set email alerts
|

Recent computational drug repositioning strategies against SARS-CoV-2

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
3
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
4
1
1

Relationship

0
6

Authors

Journals

citations
Cited by 7 publications
(3 citation statements)
references
References 92 publications
0
3
0
Order By: Relevance
“…Subsequently, ritonavir-boosted nirmatrelvir (Paxlovid), molnupiravir, and certain anti-SARS-CoV-2 monoclonal antibodies received emergencyuse authorizations from the FDA for the treatment of COVID-19 [5][6][7]. Many emerging methods [8][9][10][11][12][13][14][15][16][17][18] are being developed for drug screening and repurposing to identify antiviral targets for the treatment of COVID-19.…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Subsequently, ritonavir-boosted nirmatrelvir (Paxlovid), molnupiravir, and certain anti-SARS-CoV-2 monoclonal antibodies received emergencyuse authorizations from the FDA for the treatment of COVID-19 [5][6][7]. Many emerging methods [8][9][10][11][12][13][14][15][16][17][18] are being developed for drug screening and repurposing to identify antiviral targets for the treatment of COVID-19.…”
Section: Introductionmentioning
confidence: 99%
“…Membership grades for the MDM problem are de ned as follows: . (21) and (22) are obtained by using the one-side linear membership functions expressed in Eq (15)…”
mentioning
confidence: 99%
“…Other works have also researched on mental diseases [460] drugs or antidiabetic treatments [461], [462]. Further and more comprehensive lists of works researching in repurposing medicines to treat this SARS-CoV-2 pandemic disease can be found elsewhere [463]- [468].…”
Section: Repurposing Drugs To Treat Covid-19mentioning
confidence: 99%